Insider Trades18 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 11, 2026 | Sell | SEPN | Elizabeth Bhatt | President and COO | 50,000 | $24.89 | $1.8B | -24.64% | +181.71% | $1.2M | +0.00% | 10b5-1 | Trim |
| Aug 3, 2026 | Sell | SEPN | Daniel D. Long | SVP, Drug Discovery | 6,668 | $18.61 | $1.8B | -24.64% | +181.71% | $124.1K | +0.00% | 10b5-1 | Trim |
| Jul 15, 2026 | Sell | SEPN | Elizabeth Bhatt | President and COO | 8,000 | $20.40 | $1.8B | -24.64% | +181.71% | $163.2K | +0.00% | 10b5-1 | Trim |
| Jul 1, 2026 | Sell | SEPN | Daniel D. Long | SVP, Drug Discovery | 6,666 | $18.56 | $1.8B | -24.64% | +181.71% | $123.7K | +0.00% | 10b5-1 | Trim |
| Jun 29, 2026 | Sell | SEPN | Samira Shaikhly | Chief People Officer | 4,356 | $20.99 | $1.8B | -24.64% | +181.71% | $91.5K | +0.00% | 10b5-1 | Trim |
| Jun 22, 2026 | Sell | SEPN | Daniel D. Long | SVP, Drug Discovery | 30,000 | $20.47 | $1.8B | -24.64% | +181.71% | $614.0K | +0.00% | 10b5-1 | Trim |
| Jun 12, 2026 | Sell | SEPN | Samira Shaikhly | Chief People Officer | 12,500 | $23.39 | $1.8B | -24.64% | +181.71% | $292.3K | +0.00% | 10b5-1 | Trim |
| Jun 1, 2026 | Sell | SEPN | Samira Shaikhly | Chief People Officer | 11,870 | $15.40 | $1.8B | -24.64% | +181.71% | $182.8K | +0.00% | 10b5-1 | Trim |
| May 26, 2026 | Sell | SEPN | Samira Shaikhly | Chief People Officer | 23,596 | $18.44 | $1.8B | -24.64% | +181.71% | $435.0K | +0.00% | 10b5-1 | Trim |
| Apr 15, 2026 | Sell | SEPN | Elizabeth Bhatt | President and COO | 8,000 | $15.57 | $1.8B | -24.64% | +181.71% | $124.6K | +0.00% | 10b5-1 | Trim |
| Mar 2, 2026 | Sell | SEPN | Samira Shaikhly | Chief People Officer | 140,906 | $14.97 | $1.8B | -24.64% | +181.71% | $2.1M | +0.00% | 10b5-1 | Trim |
| Feb 18, 2026 | Sell | SEPN | Elizabeth Bhatt | President and COO | 8,000 | $17.89 | $1.8B | -24.64% | +181.71% | $143.1K | +0.00% | 10b5-1 | Trim |
| Nov 10, 2025 | Sell | SEPN | Daniel D. Long | SVP, Drug Discovery | 3,501 | $18.06 | $1.8B | -24.64% | +181.71% | $63.2K | -3.63% | — | Trim |
| Aug 18, 2025 | Buy | SEPN | Uwe Klein | SVP, Biological Sciences | 23,008 | $4.10 | $1.8B | -24.64% | +181.71% | $94.4K | +29.38% | — | Trim |
| Apr 2, 2025 | Buy | SEPN | Jeffrey Finer | CEO and President | 55,000 | $2.76 | $1.8B | -24.64% | +181.71% | $151.8K | +2.30% | — | Trim |
| Feb 25, 2025 | Buy | SEPN | Gil M Labrucherie | Chief Financial Officer | 10,000 | $5.69 | $1.8B | -24.64% | +181.71% | $56.9K | +15.09% | — | Trim |
| Feb 25, 2025 | Buy | SEPN | Jeffrey Finer | CEO and President | 17,000 | $5.70 | $1.8B | -24.64% | +181.71% | $97.0K | +0.74% | — | Trim |
| Feb 19, 2025 | Buy | SEPN | Gil M Labrucherie | Chief Financial Officer | 30,000 | $5.74 | $1.8B | -24.64% | +181.71% | $172.3K | +84.51% | — | Trim |